Astrana Health (ASTH) Q2 FY26 earnings call: guidance and Q&A

Astrana Health's AI-native operating system integrates data, workflows, clinical decision-making, and financial accountability across the enterprise, creating a durable competitive advantage. This unified platform enables AI agents to work seamlessly, leading to intelligent automation that scales and creates value. The system has reduced handling time by over 50% in claims operations and referral management, creating operational capacity equivalent to approximately 60 full-time employees over the past 12 months. This efficiency contributed to a 210 basis point year-over-year improvement in G&A as a percentage of revenue in Q2 FY26, with expectations to exit the year at approximately 6%.

The company continues to grow responsibly, balancing growth with profitability by onboarding new cohorts that generate stronger risk-adjusted returns due to the improving AI-native operating system. This allows for accelerating growth without compromising underwriting standards. New Medicare Advantage agreements were signed in Hawaii and Texas, and existing relationships expanded in California. Astrana is also prudently progressing into full-risk arrangements, with 81% of capitation revenue and 42% of membership now from such arrangements, which are performing in line with underwriting expectations. The expansion markets, including a delegated full-risk partnership in Texas, continue to validate the operating model's portability.

Astrana manages medical cost trends through better care, utilizing AI to extend clinicians' reach across a larger patient population without compromising quality. Overall medical cost trend year-to-date remains slightly better than the full-year assumption of approximately 5.2%. Medicare Advantage and original Medicare performed favorably, while Medicaid cost trend was in line with expectations. Commercial trend ran slightly above expectations in Q2, but management is confident in its ability to manage these trends. The flagship MSSP ACO ranked 7th out of 476 nationwide, and the ACO REACH entity ranked in the top 15% nationally for net shared savings in 2024.

One year after closing the Prospect acquisition, Astrana Health has systematically integrated it onto its operating system, unifying clinical operations and embedding proprietary technology. This approach has been validated by gross provider retention remaining above 99% and operating expense synergies tracking at the high end of the $12 million to $15 million annual target. Medical cost trend within the legacy Prospect business is also running slightly ahead of expectations, establishing a strong operational and clinical foundation for future improvement.

Astrana is actively positioning its portfolio for long-term value creation, including rebalancing portions of its Medi-Cal business in California by transitioning tens of thousands of members from professional risk to full-risk arrangements over the next 12 months. This is a strategic move to align performance with financial outcomes amidst changes in the state's Medicaid program. The company also reinvested a substantial portion of its Q2 outperformance, in the mid- to high single-digit millions, into attractive long-term growth opportunities such as new payer contracts and provider partnerships, aiming to compound earnings power over time^⏳.